LTBK-04. LATE BREAKING ABSTRACT: MEK162 (binimetinib) in children with progressive or recurrent low-grade glioma: a multi-institutional phase II and target validation study

BACKGROUND: RAS/RAF/MEK/ERK pathway activation is the primary driver for most pediatric low-grade gliomas (pLGG). MEK162 (binimetinib) is an orally bioavailable MEK1/2 inhibitor with superior brain penetration in a preclinical model. The primary objective of this multi-institutional phase II and tar...

Descripción completa

Detalles Bibliográficos
Autores principales: Robison, Nathan, Pauly, Jasmine, Malvar, Jemily, Gardner, Sharon, Allen, Jeffrey, Margol, Ashley, MacDonald, Tobey, Bendel, Anne, Kilburn, Lindsay, Cluster, Andrew, Bowers, Daniel, Dorris, Kathleen, Ullrich, Nicole, De Mola, Rebecca Loret, Alva, Elizabeth, Leary, Sarah, Baxter, Patricia, Khatib, Ziad, Cohen, Kenneth, Davidson, Tom Belle, Plant, Ashley, Bandopadhayay, Pratiti, Stopka, Sylwia, Agar, Nathalie, Wright, Karen, Nelson, Marvin, Chi, Yueh-Yun, Kieran, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Late Breaking Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189933/
http://dx.doi.org/10.1093/neuonc/noac079.716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189933/
http://dx.doi.org/10.1093/neuonc/noac079.716

Ejemplares similares